Published financial brief
4039B
ELEDON PHARMACEUTICALS INC
- As of
- 2024-12-31
- Source
- Supabase fundamentals
- Calculator
- financial-roic-1.0.0
- Published
- 7/26/2026
3 data notes
- Input provenance requires review.
- A ratio denominator is near zero.
- One or more values are unavailable.
Exact-period record
Fundamentals
5 reported periods
| Metric | FY 20202020-12-31 | FY 20212021-12-31 | FY 20222022-12-31 | FY 20232023-12-31 | FY 20242024-12-31 |
|---|---|---|---|---|---|
| Financial statements | |||||
| RevenueUSD millions | 0 | 0 | 0 | 0 | 0 |
| Cost of goods soldUSD millions | 0 | 0 | 0 | 0 | 0 |
| Selling, general and administrative expenseUSD millions | 16.2 | 36.9 | 39.8 | 43 | 70.6 |
| Depreciation and amortizationUSD millions | 0 | 0 | 0 | 0 | 0 |
| Net incomeUSD millions | -22.8 | -34.5 | -88 | -116.5 | -36.2 |
| Operating profit (EBIT)USD millions | -16.2 | -36.9 | -39.8 | -43 | -70.6 |
| Income taxesUSD millions | -0.4 | -2.4 | 0 | 0 | 0.4 |
| Short-term debtUSD millions | 0.1 | 0.4 | 0.4 | 0.4 | 0.3 |
| Long-term debtUSD millions | 0 | 0.4 | 0.4 | 0 | 0.6 |
| Cash and equivalentsUSD millions | 114.2 | 84.8 | 56.4 | 51.1 | 140.2 |
| ReceivablesUSD millions | 0.1 | 0 | 0 | 0 | 0 |
| InventoryUSD millions | 0 | 0 | 0 | 0 | 0 |
| PayablesUSD millions | 1.4 | 1.8 | 2.2 | 1 | 5.8 |
| Net property, plant and equipmentUSD millions | 0.1 | 0.8 | 0.7 | 0.4 | 0.9 |
| Capital expenditureUSD millions | 0 | 0 | 0 | 0 | 0 |
| Operating cash flowUSD millions | -15.2 | -28.9 | -28.4 | -39.5 | -47.3 |
| Prepaid expensesUSD millions | 1.3 | 3.5 | 3.1 | 4.9 | 2.8 |
| AccrualsUSD millions | 1 | 2.2 | 3.9 | 2.5 | 5.4 |
| EBITDAUSD millions | -16.2 | -36.9 | -39.8 | -43 | -70.6 |
| Working capitalUSD millions | 113.2 | 83.9 | 53 | 52.2 | 132.2 |
| Working capital requirementUSD millions | -1.3 | -1.8 | -2.2 | -1 | -5.8 |
| Total debtUSD millions | 0.1 | 0.8 | 0.7 | 0.4 | 1 |
| Free cash flowUSD millions | -15.2 | -28.9 | -28.4 | -39.5 | -47.3 |
| Unlevered free cash flowUSD millions | -14.7 | -34 | -39.4 | -44.2 | -65.7 |
| Returns and ratios | |||||
| ROICratio | -12.4% | -26.8% | -128.6% | -135.3% | -256.8% |
| Pre-tax ROICratio | -12.6% | -28.7% | -128.6% | -135.3% | -256.8% |
| Effective tax rateratio | 1.7% | 6.4% | 0% | 0% | 0% |
| Revenue growthratio | —missing | —missing | —missing | —missing | —missing |
| EBIT / Revenueratio | —missing | —missing | —missing | —missing | —missing |
| Revenue / Invested capitalmultiple | 0× | 0× | 0× | 0× | 0× |
| Cogs Over Revenuesratio | —missing | —missing | —missing | —missing | —missing |
| Sga Over Revenuesratio | —missing | —missing | —missing | —missing | —missing |
| Da Over Revenuesratio | —missing | —missing | —missing | —missing | —missing |
| Nfa Over Revenuesratio | —missing | —missing | —missing | —missing | —missing |
| Wcr Over Revenuesratio | —missing | —missing | —missing | —missing | —missing |
| Debt Over Ebitdamultiple | —missing | —missing | —missing | —missing | —missing |
| St Debt Over Cashmultiple | 0× | 0× | 0.01× | 0.01× | 0× |
| Interest Over Ebitdamultiple | —missing | —missing | —missing | —missing | —missing |
| Interest Over Nocf Nicfmultiple | 0× | 0× | 0× | 0× | 0× |
| Nsf Over Wcrmultiple | 90.81× | 46.59× | 25.48× | 52.45× | 23.98× |
Ask this snapshot
Research assistant
4039B · annualSnapshot b08f54b8
Answers use only this published snapshot. The assistant will say when the data is insufficient and does not create forecasts, scenarios, or investment advice.
0 / 2,000